4/27/2012

Amgen and PRA, a clinical-research organization, agreed to collaborate in a series of late-stage trials to develop the former's biosimilar drugs. The deal makes PRA the exclusive provider of CRO services for Amgen's biosimilars.

Full Story:
MedCityNews.com

Related Summaries